Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer.
Fatty acid oxidation
Gastric cancer
Lipid uptake
Lipolysis-stimulated lipoprotein receptor
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
05
03
2024
accepted:
02
09
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
18
9
2024
Statut:
aheadofprint
Résumé
Lipolysis-stimulated lipoprotein receptor (LSR), a lipid receptor, is associated with cancer progression. However, detailed effects on intracellular metabolism are unclear. We aimed to elucidate the mechanism of LSR-mediated lipid metabolism in gastric cancer. We investigated lipid metabolic changes induced by lipoprotein administration in gastric cancer cells and evaluated the significance of LSR expression and lipid droplets formation in gastric cancer patients. The efficacy of inhibiting β-oxidation in gastric cancer cells was also examined in vitro and vivo. In gastric cancer cells, LSR promoted cellular uptake of lipoprotein and cell proliferation. Furthermore, the inhibition of LSR in gastric cancer cells expressing high levels of LSR counteracted both effects. Immunohistochemical analysis of human gastric cancer tissues showed that the increase in lipid droplets via LSR is a factor that influences prognosis. Lipidomics analysis of LSR-high-expressing gastric cancer cells revealed an increase in β-oxidation. Based on these results, we used etomoxir, a β-oxidation inhibitor, and found that it inhibited cell proliferation as well as the suppression of LSR. Similarly, in a mouse xenograft model of LSR-highly expressing gastric cancer cells, the tumor growth effect of high-fat diet feeding was counteracted by etomoxir, consistent with the Ki-67 labeling index. We demonstrated that lipids are taken up into gastric cancer cells via LSR and cause an increase in β-oxidation, resulting in the promotion of cancer progression. Controlling LSR-mediated lipid metabolism may be a novel therapeutic strategy for gastric cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Lipolysis-stimulated lipoprotein receptor (LSR), a lipid receptor, is associated with cancer progression. However, detailed effects on intracellular metabolism are unclear. We aimed to elucidate the mechanism of LSR-mediated lipid metabolism in gastric cancer.
METHODS
METHODS
We investigated lipid metabolic changes induced by lipoprotein administration in gastric cancer cells and evaluated the significance of LSR expression and lipid droplets formation in gastric cancer patients. The efficacy of inhibiting β-oxidation in gastric cancer cells was also examined in vitro and vivo.
RESULTS
RESULTS
In gastric cancer cells, LSR promoted cellular uptake of lipoprotein and cell proliferation. Furthermore, the inhibition of LSR in gastric cancer cells expressing high levels of LSR counteracted both effects. Immunohistochemical analysis of human gastric cancer tissues showed that the increase in lipid droplets via LSR is a factor that influences prognosis. Lipidomics analysis of LSR-high-expressing gastric cancer cells revealed an increase in β-oxidation. Based on these results, we used etomoxir, a β-oxidation inhibitor, and found that it inhibited cell proliferation as well as the suppression of LSR. Similarly, in a mouse xenograft model of LSR-highly expressing gastric cancer cells, the tumor growth effect of high-fat diet feeding was counteracted by etomoxir, consistent with the Ki-67 labeling index.
CONCLUSIONS
CONCLUSIONS
We demonstrated that lipids are taken up into gastric cancer cells via LSR and cause an increase in β-oxidation, resulting in the promotion of cancer progression. Controlling LSR-mediated lipid metabolism may be a novel therapeutic strategy for gastric cancer.
Identifiants
pubmed: 39294388
doi: 10.1007/s10120-024-01552-z
pii: 10.1007/s10120-024-01552-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP17im0210606
Organisme : Japan Agency for Medical Research and Development
ID : JP20im0210111
Informations de copyright
© 2024. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
Références
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.
doi: 10.1016/S0140-6736(20)31288-5
pubmed: 32861308
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Yanagimoto Y, Kurokawa Y, Doki Y. Essential updates 2021/2022: Perioperative and surgical treatments for gastric and esophagogastric junction cancer. Ann Gastroenterol Surg. 2023;7:698–708.
doi: 10.1002/ags3.12711
pubmed: 37663969
pmcid: 10472390
Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg. 2021;5:446–56.
doi: 10.1002/ags3.12439
pubmed: 34337293
pmcid: 8316740
Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155–70.
doi: 10.1038/s41575-022-00703-w
pubmed: 36344677
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669–80.
doi: 10.1038/s41568-021-00378-6
pubmed: 34272515
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
doi: 10.1126/science.123.3191.309
pubmed: 13298683
Hsu PP, Sabatini DM. Cancer cell metabolism: warburg and beyond. Cell. 2008;134:703–7.
doi: 10.1016/j.cell.2008.08.021
pubmed: 18775299
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
doi: 10.1126/science.1160809
pubmed: 19460998
pmcid: 2849637
Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021. https://doi.org/10.3390/cells10051056 .
doi: 10.3390/cells10051056
pubmed: 33946927
pmcid: 8146072
Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38:27.
pubmed: 29784041
Ohshima K, Morii E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites. 2021. https://doi.org/10.3390/metabo11010028 .
doi: 10.3390/metabo11010028
pubmed: 33401771
pmcid: 7824065
Tan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13:4554.
doi: 10.1038/s41467-022-32101-w
pubmed: 35931676
pmcid: 9356138
Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, et al. LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake. Cancer Res. 2018;78:516–27.
doi: 10.1158/0008-5472.CAN-17-0910
pubmed: 29187404
Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, et al. Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. Oncotarget. 2018;9:32917–28.
doi: 10.18632/oncotarget.25952
pubmed: 30250639
pmcid: 6152476
Nagase Y, Hiramatsu K, Funauchi M, Shiomi M, Masuda T, Kakuda M, et al. Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer. BMC Cancer. 2022;22:679.
doi: 10.1186/s12885-022-09789-6
pubmed: 35729527
pmcid: 9210735
Yen FT, Masson M, Clossais-Besnard N, André P, Grosset JM, Bougueleret L, et al. Molecular cloning of a lipolysis-stimulated remnant receptor expressed in the liver. J Biol Chem. 1999;274:13390–8.
doi: 10.1074/jbc.274.19.13390
pubmed: 10224102
Bihain BE, Yen FT. The lipolysis stimulated receptor: a gene at last. Curr Opin Lipidol. 1998;9:221–4.
doi: 10.1097/00041433-199806000-00006
pubmed: 9645504
Sugase T, Takahashi T, Serada S, Nakatsuka R, Fujimoto M, Ohkawara T, et al. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice. Int J Cancer. 2017;140:2608–21.
doi: 10.1002/ijc.30666
pubmed: 28233302
Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, et al. SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal squamous cell carcinoma. Cancer Res. 2017;77:6975–86.
doi: 10.1158/0008-5472.CAN-17-1525
pubmed: 29042418
Iwahashi N, Ikezaki M, Fujimoto M, Komohara Y, Fujiwara Y, Yamamoto M, et al. Lipid droplet accumulation independently predicts poor clinical prognosis in high-grade serous ovarian carcinoma. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13205251 .
doi: 10.3390/cancers13205251
pubmed: 34680399
pmcid: 8700357
Fujimoto M, Matsuzaki I, Yamamoto Y, Yoshizawa A, Warigaya K, Iwahashi Y, et al. Adipophilin expression in cutaneous malignant melanoma. J Cutan Pathol. 2017;44:228–36.
doi: 10.1111/cup.12868
pubmed: 27886404
Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue .IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13(1):27–9.
pubmed: 13032945
Pascual G, Avgustinova A, Mejetta S, Martín M, Castellanos A, Attolini CS, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541:41–5.
doi: 10.1038/nature20791
pubmed: 27974793
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17:1498–503.
doi: 10.1038/nm.2492
pubmed: 22037646
pmcid: 4157349
Judge A, Dodd MS. Metabolism. Essays Biochem. 2020;64:607–47.
doi: 10.1042/EBC20190041
pubmed: 32830223
pmcid: 7545035
Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol. 2019;20:137–55.
doi: 10.1038/s41580-018-0085-z
pubmed: 30523332
pmcid: 6746329
Jin Y, Tan Y, Wu J, Ren Z. Lipid droplets: a cellular organelle vital in cancer cells. Cell Death Discov. 2023;9:254.
doi: 10.1038/s41420-023-01493-z
pubmed: 37474495
pmcid: 10359296
García JM, Peña C, García V, Domínguez G, Muñoz C, Silva J, et al. Prognostic value of LISCH7 mRNA in plasma and tumor of colon cancer patients. Clin Cancer Res. 2007;13:6351–8.
doi: 10.1158/1078-0432.CCR-07-0882
pubmed: 17975147
Zhang M, Ma C. LSR promotes cell proliferation and invasion in lung cancer. Comput Math Methods Med. 2021;2021:6651907.
pubmed: 33763152
pmcid: 7964108
Fujiwara N, Nakagawa H, Enooku K, Kudo Y, Hayata Y, Nakatsuka T, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018;67:1493–504.
doi: 10.1136/gutjnl-2017-315193
pubmed: 29437870
Okushin K, Tsutsumi T, Ikeuchi K, Kado A, Enooku K, Fujinaga H, et al. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet. PLoS ONE. 2020;15: e0234750.
doi: 10.1371/journal.pone.0234750
pubmed: 32785220
pmcid: 7423142
Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, et al. Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials. Pharmacol Rev. 2022;74:506–51.
doi: 10.1124/pharmrev.121.000408
pubmed: 35710135
Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021;596:576–82.
doi: 10.1038/s41586-021-03796-6
pubmed: 34381210
pmcid: 9209846
Schlaepfer IR, Joshi M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology. 2020. https://doi.org/10.1210/endocr/bqz046 .
doi: 10.1210/endocr/bqz046
pubmed: 31900483
Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, et al. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Mol Cancer Res. 2020;18:1088–98.
doi: 10.1158/1541-7786.MCR-19-1057
pubmed: 32198139
pmcid: 7335321
Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond). 2000;99:27–35.
doi: 10.1042/cs0990027
pubmed: 10887055
Hübinger A, Weikert G, Wolf HP, Gries FA. The effect of etomoxir on insulin sensitivity in type 2 diabetic patients. Horm Metab Res. 1992;24:115–8.
doi: 10.1055/s-2007-1003271
pubmed: 1577399
Hinderling VB, Schrauwen P, Langhans W, Westerterp-Plantenga MS. The effect of etomoxir on 24-h substrate oxidation and satiety in humans. Am J Clin Nutr. 2002;76:141–7.
doi: 10.1093/ajcn/76.1.141
pubmed: 12081827
Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond). 2007;113:205–12.
doi: 10.1042/CS20060307
pubmed: 17319797
Yao CH, Liu GY, Wang R, Moon SH, Gross RW, Patti GJ. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation. PLoS Biol. 2018;16: e2003782.
doi: 10.1371/journal.pbio.2003782
pubmed: 29596410
pmcid: 5892939